Zhangzhou Pientzehuang Pharmaceutical., Ltd (600436.SS)
CNY 220.76
(0.79%)
CNY 220.76
(0.79%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 3.57 Billion CNY | 7.58% |
| 2022 | 3.12 Billion CNY | 2.45% |
| 2021 | 3.04 Billion CNY | 46.99% |
| 2020 | 2.07 Billion CNY | 18.96% |
| 2019 | 1.73 Billion CNY | 19.9% |
| 2018 | 1.33 Billion CNY | 39.92% |
| 2017 | 1.01 Billion CNY | 47.76% |
| 2016 | 684.85 Million CNY | 14.22% |
| 2015 | 598.47 Million CNY | 7.58% |
| 2014 | 568.07 Million CNY | 0.65% |
| 2013 | 557.93 Million CNY | 24.7% |
| 2012 | 453.63 Million CNY | 35.38% |
| 2011 | 325.83 Million CNY | 47.01% |
| 2010 | 253.23 Million CNY | 35.23% |
| 2009 | 168.9 Million CNY | -9.54% |
| 2008 | 184.92 Million CNY | 28.49% |
| 2007 | 143.81 Million CNY | 5.84% |
| 2006 | 136.87 Million CNY | -3.54% |
| 2005 | 142.67 Million CNY | 63.85% |
| 2004 | 87.07 Million CNY | -12.04% |
| 2003 | 98.99 Million CNY | 0.73% |
| 2002 | 98.27 Million CNY | 10.81% |
| 2001 | 88.68 Million CNY | 8.22% |
| 2000 | 81.95 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q3 | 1.13 Billion CNY | 28.26% |
| 2024 Q2 | 884.88 Million CNY | -25.03% |
| 2024 Q1 | 1.19 Billion CNY | 115.4% |
| 2023 Q2 | 928.48 Million CNY | -2.64% |
| 2023 Q3 | 1.05 Billion CNY | 13.62% |
| 2023 FY | - CNY | 7.58% |
| 2023 Q1 | 953.6 Million CNY | 80.12% |
| 2023 Q4 | 463.85 Million CNY | -56.03% |
| 2022 FY | - CNY | 2.45% |
| 2022 Q4 | 529.43 Million CNY | -41.12% |
| 2022 Q1 | 840.34 Million CNY | 87.36% |
| 2022 Q2 | 771.26 Million CNY | -8.22% |
| 2022 Q3 | 899.17 Million CNY | 16.58% |
| 2021 FY | - CNY | 46.99% |
| 2021 Q1 | 688.49 Million CNY | 90.88% |
| 2021 Q4 | 448.52 Million CNY | -59.31% |
| 2021 Q3 | 1.1 Billion CNY | 63.71% |
| 2021 Q2 | 673.27 Million CNY | -2.21% |
| 2020 Q2 | 478.85 Million CNY | -18.11% |
| 2020 Q3 | 557.74 Million CNY | 16.47% |
| 2020 Q4 | 360.69 Million CNY | -35.33% |
| 2020 FY | - CNY | 18.96% |
| 2020 Q1 | 584.75 Million CNY | 75.81% |
| 2019 Q4 | 332.6 Million CNY | -23.44% |
| 2019 Q3 | 434.46 Million CNY | 2.88% |
| 2019 FY | - CNY | 19.9% |
| 2019 Q1 | 496.73 Million CNY | 61.24% |
| 2019 Q2 | 422.3 Million CNY | -14.98% |
| 2018 FY | - CNY | 39.92% |
| 2018 Q1 | 382.66 Million CNY | 60.17% |
| 2018 Q3 | 365.45 Million CNY | 8.69% |
| 2018 Q4 | 308.07 Million CNY | -15.7% |
| 2018 Q2 | 336.24 Million CNY | -12.13% |
| 2017 Q1 | 250.95 Million CNY | 191.75% |
| 2017 Q4 | 238.9 Million CNY | -4.34% |
| 2017 Q2 | 275.59 Million CNY | 9.82% |
| 2017 FY | - CNY | 47.76% |
| 2017 Q3 | 249.74 Million CNY | -9.38% |
| 2016 Q1 | 178.09 Million CNY | 15.89% |
| 2016 Q4 | 86.01 Million CNY | -56.15% |
| 2016 Q3 | 196.15 Million CNY | -6.72% |
| 2016 Q2 | 210.29 Million CNY | 18.08% |
| 2016 FY | - CNY | 14.22% |
| 2015 Q2 | 164.32 Million CNY | 8.45% |
| 2015 FY | - CNY | 7.58% |
| 2015 Q4 | 153.66 Million CNY | 7.19% |
| 2015 Q3 | 143.35 Million CNY | -12.76% |
| 2015 Q1 | 151.51 Million CNY | -25.87% |
| 2014 Q4 | 204.38 Million CNY | 129.94% |
| 2014 FY | - CNY | 0.65% |
| 2014 Q1 | 142.56 Million CNY | 18.59% |
| 2014 Q3 | 88.88 Million CNY | -29.57% |
| 2014 Q2 | 126.2 Million CNY | -11.48% |
| 2013 Q1 | 137.81 Million CNY | 2.45% |
| 2013 Q2 | 144.42 Million CNY | 4.8% |
| 2013 Q3 | 150.55 Million CNY | 4.25% |
| 2013 Q4 | 120.21 Million CNY | -20.15% |
| 2013 FY | - CNY | 24.7% |
| 2012 Q4 | 134.51 Million CNY | 23.1% |
| 2012 Q3 | 109.27 Million CNY | 0.41% |
| 2012 Q2 | 108.83 Million CNY | 12.98% |
| 2012 Q1 | 96.32 Million CNY | 8.6% |
| 2012 FY | - CNY | 35.38% |
| 2011 Q4 | 88.69 Million CNY | 0.2% |
| 2011 FY | - CNY | 47.01% |
| 2011 Q3 | 88.52 Million CNY | 32.64% |
| 2011 Q2 | 66.73 Million CNY | -15.62% |
| 2011 Q1 | 79.09 Million CNY | -8.75% |
| 2010 FY | - CNY | 35.23% |
| 2010 Q3 | 44.56 Million CNY | 16.33% |
| 2010 Q2 | 38.3 Million CNY | -8.13% |
| 2010 Q4 | 86.67 Million CNY | 94.49% |
| 2010 Q1 | 41.69 Million CNY | 27.55% |
| 2009 Q4 | 32.69 Million CNY | -20.66% |
| 2009 Q2 | 46.53 Million CNY | 32.09% |
| 2009 Q1 | 35.23 Million CNY | -47.94% |
| 2009 Q3 | 41.2 Million CNY | -11.47% |
| 2009 FY | - CNY | -9.54% |
| 2008 Q3 | 40.07 Million CNY | 72.48% |
| 2008 Q4 | 67.67 Million CNY | 68.87% |
| 2008 FY | - CNY | 28.49% |
| 2008 Q1 | 40.02 Million CNY | 42.88% |
| 2008 Q2 | 23.23 Million CNY | -41.94% |
| 2007 Q4 | 28.01 Million CNY | -6.27% |
| 2007 Q3 | 29.88 Million CNY | -19.06% |
| 2007 Q2 | 36.92 Million CNY | 0.21% |
| 2007 Q1 | 36.84 Million CNY | -3.69% |
| 2007 FY | - CNY | 5.84% |
| 2006 Q3 | 34.49 Million CNY | -19.91% |
| 2006 Q4 | 38.25 Million CNY | 10.9% |
| 2006 Q2 | 43.07 Million CNY | 58.31% |
| 2006 FY | - CNY | -3.54% |
| 2006 Q1 | 27.2 Million CNY | -40.22% |
| 2005 FY | - CNY | 63.85% |
| 2005 Q4 | 45.51 Million CNY | 8.22% |
| 2005 Q3 | 42.05 Million CNY | 31.78% |
| 2005 Q2 | 31.91 Million CNY | 37.58% |
| 2005 Q1 | 23.19 Million CNY | 197.51% |
| 2004 Q4 | 7.79 Million CNY | -73.86% |
| 2004 Q2 | 44.76 Million CNY | 255.15% |
| 2004 FY | - CNY | -12.04% |
| 2004 Q1 | 12.6 Million CNY | -63.8% |
| 2004 Q3 | 29.82 Million CNY | -33.37% |
| 2003 Q3 | 20.77 Million CNY | -1.76% |
| 2003 Q2 | 21.14 Million CNY | 4.44% |
| 2003 Q4 | 34.82 Million CNY | 67.63% |
| 2003 FY | - CNY | 0.73% |
| 2003 Q1 | 20.24 Million CNY | -24.35% |
| 2002 FY | - CNY | 10.81% |
| 2002 Q4 | 26.76 Million CNY | 16.34% |
| 2002 Q3 | 23 Million CNY | 0.0% |
| 2001 FY | - CNY | 8.22% |
| 2000 FY | - CNY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Jiangsu Hengrui Medicine Co., Ltd. | 5.54 Billion CNY | 35.462% |
| Zhejiang CONBA Pharmaceutical Co.,Ltd. | 1.12 Billion CNY | -216.865% |
| Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd. | 192.74 Million CNY | -1755.109% |
| Aurora Optoelectronics Co.,Ltd. | -509.76 Million CNY | 801.434% |
| Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd | -14.11 Million CNY | 25438.257% |
| NanJing Pharmaceutical Company Limited | 1.61 Billion CNY | -120.81% |
| GuangYuYuan Chinese Herbal Medicine Co., Ltd. | 157.93 Million CNY | -2163.939% |
| Tonghua Dongbao Pharmaceutical Co., Ltd. | 1.55 Billion CNY | -129.657% |